In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C results in $30mm for Mako Surgical

Executive Summary

Mako Surgical (minimally invasive devices for knee surgery) raised $30mm in its Series C financing round led by Tudor Investment. New backer Ziegler Meditech Equity Partners was joined by returning shareholders Exxel Group, MDS Capital, Aperture Venture Partners, Ivy Healthcare Capital, and Sycamore Ventures. The company will use the proceeds to expand the presence of its Makoplasty product for knee osteoarthritis and to develop next-generation technologies and implants.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies